Skip to main content

Advertisement

ADVERTISEMENT

Commentary

Julie Schulz headshot
Commentary
03/27/2024

By Julie Schulz, MD, MPH

By Julie Schulz, MD, MPH
Chronic kidney disease (CKD) is an insidious condition with devastating consequences when detected and treated too late. While primary care physicians usually make the initial diagnosis, regular screening is not routine for the general...
Chronic kidney disease (CKD) is an insidious condition with devastating consequences when detected and treated too late. While primary care physicians usually make the initial diagnosis, regular screening is not routine for the general...
Chronic kidney disease (CKD) is...
03/27/2024
First Report Managed Care
Kevin/Avikar Hedshots
Commentary
03/20/2024

Kevin Riley, CEO, President, Zyter|TruCare; Avikar Govil, Insights Health Product Manager, Zyter|TruCare

Kevin Riley, CEO, President, Zyter|Tr...
The rapid evolution of Generative Artificial Intelligence (Gen AI) is fundamentally transforming the health care industry, ushering in an era of increased personalization, efficiency, and improved patient outcomes. In this commentary, experts...
The rapid evolution of Generative Artificial Intelligence (Gen AI) is fundamentally transforming the health care industry, ushering in an era of increased personalization, efficiency, and improved patient outcomes. In this commentary, experts...
The rapid evolution of...
03/20/2024
First Report Managed Care

Advertisement

James Wallace Headshot
Commentary
03/08/2024

James Wallace, CEO of DecisionRx

James Wallace, CEO of DecisionRx ...
Medication adherence poses a significant challenge in health care, with far-reaching consequences for patients and the health care system. It is a complex issue influenced by various factors, including undesirable side effects, lack of...
Medication adherence poses a significant challenge in health care, with far-reaching consequences for patients and the health care system. It is a complex issue influenced by various factors, including undesirable side effects, lack of...
Medication adherence poses a...
03/08/2024
First Report Managed Care
Commentary
03/01/2024

Amit Gupta, MD, Medical Director, Clinical Strategy at Sagility

Amit Gupta, MD, Medical Director, Cli...
Utilization management is evolving from a cost-centric process to a focus on quality of care, with trends including exception-based authorization handling and value-based arrangements to reduce administrative burden and provider abrasion.
Utilization management is evolving from a cost-centric process to a focus on quality of care, with trends including exception-based authorization handling and value-based arrangements to reduce administrative burden and provider abrasion.
Utilization management is...
03/01/2024
First Report Managed Care
Commentary
03/01/2024

Michael Gould, AVP, Interoperability Strategy at ZeOmega

Michael Gould, AVP, Interoperability ...
CMS has published the Interoperability and Prior Authorization final rule to drive transformative outcomes in the health care ecosystem, requiring payers and providers to adopt new standards and FHIR APIs to reduce inefficiencies and improve...
CMS has published the Interoperability and Prior Authorization final rule to drive transformative outcomes in the health care ecosystem, requiring payers and providers to adopt new standards and FHIR APIs to reduce inefficiencies and improve...
CMS has published the...
03/01/2024
First Report Managed Care

Advertisement

Alex Sommer
Commentary
02/14/2024

Alex Sommer, vice president, State Government Affairs, Avalon Healthcare Solutions

Alex Sommer, vice president, State Go...
Biomarker bills are merely the latest in what is likely to be a wave of legislation mandating coverage of new tests and therapies that are part of the growth in precision medicine. This will make it increasingly difficult for plans to control...
Biomarker bills are merely the latest in what is likely to be a wave of legislation mandating coverage of new tests and therapies that are part of the growth in precision medicine. This will make it increasingly difficult for plans to control...
Biomarker bills are merely the...
02/14/2024
First Report Managed Care
Christie Headshot
Commentary
02/13/2024

Christie Teigland, PhD, VP of Research Science and Advanced Analytics, Inovalon

Christie Teigland, PhD, VP of Researc...
As part of the 2024 Medicare Advantage (MA) and Part D Final Rule, CMS is enhancing the Star Ratings program by implementing a Health Equity Index (HEI) reward to incentivize MA and Part D contracts with 500 or more members to address...
As part of the 2024 Medicare Advantage (MA) and Part D Final Rule, CMS is enhancing the Star Ratings program by implementing a Health Equity Index (HEI) reward to incentivize MA and Part D contracts with 500 or more members to address...
As part of the 2024 Medicare...
02/13/2024
First Report Managed Care
Commentary
01/24/2024

Lisa Kuhns, PhD

Lisa Kuhns, PhD
In January 2024, Better Therapeutics, Inc submitted a request to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its new prescription digital therapeutic (PDT) designed to treat metabolic...
In January 2024, Better Therapeutics, Inc submitted a request to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its new prescription digital therapeutic (PDT) designed to treat metabolic...
In January 2024, Better...
01/24/2024
First Report Managed Care

Advertisement

KOL Headshots
Commentary
01/23/2024
In this exclusive commentary for First Report Managed Care, health experts and business leaders share insights into predictions for the 2024 value-based care landscape. Insights highlight trends in behavioral health, AI integration,...
In this exclusive commentary for First Report Managed Care, health experts and business leaders share insights into predictions for the 2024 value-based care landscape. Insights highlight trends in behavioral health, AI integration,...
In this exclusive commentary for...
01/23/2024
First Report Managed Care
Commentary
01/12/2024

Lisa Kuhns, PhD

Lisa Kuhns, PhD
In January 2024, Better Therapeutics Inc. and Glooko Inc. announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
In January 2024, Better Therapeutics Inc. and Glooko Inc. announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
In January 2024, Better...
01/12/2024
First Report Managed Care

Advertisement